The European Medicines Agency has recommended granting a licence for treatment with autologous anti-CD19-transduced CD3+ cell therapy.
-
-
All you need to know about tafasitamab for DLBCL Tafasitamab-cxix was recently approved by the US FDA.
-
OSA is linked to increased risk for non-Hodgkin lymphoma Retrospective cohort study of more than 2 million in Korea uncovers association.
-
Insights about treating newly diagnosed MCL Session presented at ASH 2020.
-
Napabucasin can inhibit DLBCL in vitro Drug tested on DLBCL cell lines.
-
NICE approves polatuzumab vedotin for relapsed B-cell lymphoma Polatuzumab vedotin with rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma
-
Infection is common in patients treated with CD19-directed chimeric antigen receptor T-cell therapy, but it is not associated with higher mortality
-
FDA approves tafasitamab-cxix for R/R DLBCL The approval is based on the phase 2 L-MIND trial.
-
FDA approves new drug for diffuse large B-cell lymphoma The approval is based on the phase 2 L-MIND trial.
-
FDA approves first CAR T therapy for R/R MCL The approval is based on the ongoing ZUMA-2 trial.
-
FDA okays new CAR T therapy, first for mantle cell lymphoma Approval is based on the ongoing ZUMA-2 trial.
-
NICE: brentuximab vedotin for untreated sALCL Final draft guidance from NICE recommend brentuximab vedotin with CHP for untreated systemic anaplastic large cell lymphoma
-
Official figures from the Medicines and Healthcare products Regulatory Agency.
-
FDA approves tazemetostat and companion assay for R/R FL with EZH2 mutation The approval was based on an open-label, single-arm, phase 2 trial.